Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study-Reference-Cited by-同舟云学术

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study

Published:2018-01 Issue:1 Volume:19 Page:101-114
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Herbst Roy S,Redman Mary W,Kim Edward S,Semrad Thomas J,Bazhenova Lyudmila,Masters Gregory,Oettel Kurt,Guaglianone Perry,Reynolds Christopher,Karnad Anand,Arnold Susanne M,Varella-Garcia Marileila,Moon James,Mack Philip C,Blanke Charles D,Hirsch Fred R,Kelly Karen,Gandara David R

Funder

National Cancer Institute of the National Institutes of Health

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy;Herbst;Clin Lung Cancer,2009

3. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

4. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials;Yang;Lancet Oncol,2015

5. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimating individualized treatment rules by optimizing the adjusted probability of a longer survival;Statistical Methods in Medical Research;2024-07-25

2. Combined treatment with cetuximab and STA9090 has synergistic anticancer effects on human non-small cell lung cancer;Acta Biochimica et Biophysica Sinica;2024-05-30

3. Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer;Journal of Comparative Effectiveness Research;2024-05

4. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer;Frontiers in Public Health;2024-02-15

5. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-01